Home › Erectile Dysfunction › NCT06720597
EndoPAT Device for Endothelial Dysfunction in ED
Utilizing EndoPAT Device for Endothelial Dysfunction Assessment in Erectile Dysfunction and Hormonal Therapy
Who can join
Ages 18 and older · Men
Full eligibility criteria
Inclusion Criteria: * Males 18 years old and above * Diagnosed with erectile dysfunction or hypogonadism Exclusion Criteria: * Patients without the above criteria
About the study
To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound.
To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy.
To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy
What is being tested
- Daily low-dose PDE5 inhibitor therapy (drug)
- Testosterone therapy as per clinical guidelines. (drug)
Sponsor: University of California, Irvine · Participants: 120 · Started: Aug 13, 2025
Contact the study team
- Muhammed AM Hammad, MBBCh · Phone: 714-456-7005
- Elia Abou Chawareb, MD · Phone: 714-456-7005
Official record on ClinicalTrials.gov — NCT06720597
Locations in the U.S.
| California | UCI Urology | Men's Health Center, Newport Beach |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.